There have been cases of overdose when taking the drug at a dose of more than 2320 mg.
Symptoms: drowsiness or agitation, nausea, vomiting, sinus tachycardia.
Treatment: seek immediate medical attention. Gastric lavage, ECG monitoring, symptomatic therapy. Maintaining the vital functions of the body.
hypersensitivity to the active substance and / or any of the components of the drug,
children under 2 years of age.
With caution: patients with fructose intolerance, glucose-galactose malabsorption, sucrose/isomaltase deficiency (due to the presence of sucrose in Erespal® syrup), patients with diabetes mellitus (due to the presence of sucrose in the composition of Erespal® syrup).
hypersensitivity to the active substance and / or any of the components of the drug,
children under 2 years of age.
With caution: patients with fructose intolerance, glucose-galactose malabsorption, sucrose/isomaltase deficiency (due to the presence of sucrose in Fenspiride® syrup), patients with diabetes mellitus (due to the presence of sucrose in the composition of Fenspiride® syrup).
hypersensitivity to fenspiride or other components of the drug,
pregnancy,
breastfeeding period,
age up to 18 years.
With caution: simultaneous administration of sedatives, ethanol.
Special studies on the interaction of fenspiride with other drugs have not been conducted.
Due to the possible increase in the sedative effect when taking histamine H blockers1- the use of the drug Erespal is not recommended for receptors® syrup in combination with drugs that have a sedative effect, or together with alcohol.
Special studies on the interaction of fenspiride with other drugs have not been conducted.
Due to the possible increase in the sedative effect when taking histamine H blockers1- the use of the drug Fenspiride is not recommended for receptors® syrup in combination with drugs that have a sedative effect, or together with alcohol.
Special studies on the interaction of fenspiride with other drugs have not been conducted.
Due to the possible increase in the sedative effect when taking histamine H blockers1- the use of the drug Fenspiride is not recommended for receptors® in combination with drugs that have a sedative effect, or together with ethanol.
It is necessary to inform the doctor about the appearance of any adverse reactions in the patient, including those not mentioned in this description, as well as about changes in laboratory parameters during therapy.
The most common adverse reactions to the drug Erespal® observed from the digestive system.
The frequency of adverse reactions that may occur during therapy is given as the following gradation: very common (>1/10), common (>1/100, <1/10), infrequent (>1/1000, <1/100), rare (>1/10000, <1/1000), very rare (<1/10000), and unspecified frequency (frequency cannot be calculated from available data).
From the CCC side: rarely-moderate tachycardia, the severity of which decreases with a decrease in the dose of the drug, an unknown frequency-a feeling of palpitation, hypotension, possibly associated with tachycardia.
From the digestive system: often-gastrointestinal disorders, nausea, epigastric pain, unknown frequency* - diarrhea, vomiting.
From the central nervous system: rarely-drowsiness, unknown frequency* - dizziness.
Common disorders and symptoms: unknown frequency* - asthenia, increased fatigue.
From the skin and subcutaneous fat: rarely-erythema, rash, urticaria, angioedema, fixed erythema pigmentosa, unknown frequency-pruritus, toxic epidermal necrolysis, Stevens-Johnson syndrome..
*Post-registration application data.
It is necessary to inform the doctor about the appearance of any adverse reactions in the patient, including those not mentioned in this description, as well as about changes in laboratory parameters during therapy.
The most common adverse reactions to the drug Fenspiride® observed from the digestive system.
The frequency of adverse reactions that may occur during therapy is given as the following gradation: very common (>1/10), common (>1/100, <1/10), infrequent (>1/1000, <1/100), rare (>1/10000, <1/1000), very rare (<1/10000), and unspecified frequency (frequency cannot be calculated from available data).
From the CCC side: rarely-moderate tachycardia, the severity of which decreases with a decrease in the dose of the drug, an unknown frequency-a feeling of palpitation, hypotension, possibly associated with tachycardia.
From the digestive system: often-gastrointestinal disorders, nausea, epigastric pain, unknown frequency* - diarrhea, vomiting.
From the central nervous system: rarely-drowsiness, unknown frequency* - dizziness.
Common disorders and symptoms: unknown frequency* - asthenia, increased fatigue.
From the skin and subcutaneous fat: rarely-erythema, rash, urticaria, angioedema, fixed erythema pigmentosa, unknown frequency-pruritus, toxic epidermal necrolysis, Stevens-Johnson syndrome..
*Post-registration application data.
Classification of the frequency of side effects according to WHO recommendations: very often - >1/10, often - from >1/100 to <1/10, infrequently-from >1/1000 to <1/100, rarely-from >1/10000 to <1/1000, very rarely - <1/10000, including individual reports, the frequency is unknown — according to available data, it is not possible to establish the frequency of occurrence.
From the CCC side: rarely-moderate tachycardia, the severity of which decreases with a decrease in the dose of the drug, the frequency is unknown — a feeling of palpitation, a decrease in blood pressure, possibly associated with tachycardia.
From the digestive system: often-gastrointestinal disorders, nausea, epigastric pain, the frequency is unknown-diarrhea, vomiting.
From the central nervous system: rarely-drowsiness, frequency unknown-dizziness.
From the skin: rarely-erythema, rash, urticaria, angioedema, fixed erythema pigmentosa, frequency unknown-pruritus, toxic epidermal necrolysis, Stevens-Johnson syndrome.
Other: the frequency is unknown — asthenia, increased fatigue.
diseases of the upper and lower respiratory tract:
- rhinopharyngitis and laryngitis,
- tracheobronchitis,
- bronchitis (with or without chronic respiratory failure),
- bronchial asthma (as part of complex therapy),
- respiratory phenomena (cough, hoarseness of voice, sore throat) in measles, whooping cough and influenza,
- infectious diseases of the respiratory tract, accompanied by cough, in which standard antibiotic therapy is indicated.
otitis and sinusitis of various etiologies.
diseases of the upper and lower respiratory tract:
- rhinopharyngitis and laryngitis,
- tracheobronchitis,
- bronchitis (with or without chronic respiratory failure),
- bronchial asthma (as part of complex therapy),
- respiratory phenomena (cough, hoarseness of voice, sore throat) in measles, whooping cough and influenza,
- infectious diseases of the respiratory tract, accompanied by cough, in which standard antibiotic therapy is indicated.
otitis and sinusitis of various etiologies.
diseases of the upper and lower respiratory tract:
- rhinopharyngitis and laryngitis,
- tracheobronchitis,
- bronchitis (with or without chronic respiratory failure),
- bronchial asthma (as part of complex therapy),
- respiratory phenomena (cough, hoarseness of voice, sore throat) in measles, whooping cough and influenza,
- infectious diseases of the respiratory tract, accompanied by cough, when standard antibiotic therapy is indicated,
otitis and sinusitis of various etiologies.
The anti-inflammatory and anti-bronchoconstrictor activity of fenspiride is due to a decrease in the production of a number of biologically active substances (cytokines, especially TNF-α, arachidonic acid derivatives, free radicals), which play an important role in the development of inflammation and bronchospasm.
The inhibition of arachidonic acid metabolism by fenspiride is potentiated by its H1- antihistamine effect, because histamine stimulates the metabolism of arachidonic acid with the formation of PG and LT. Fenspiride blocks alpha-adrenoreceptors, the stimulation of which is accompanied by an increase in the secretion of bronchial glands. Thus, fenspiride reduces the effect of a number of factors that contribute to the hypersecretion of pro-inflammatory factors, the development of inflammation and bronchial obstruction. Fenspiride also has an antispasmodic effect.
After oral administration Tmax the drug in the blood plasma — 6 h. T1/2 the preparation is 12 hours. It is mainly excreted by the kidneys.
Fenspiride
Fenspiride
Inside. 1 table 2-3 times a day. The maximum daily dose is 240 mg. The duration of treatment is determined by the doctor.
R03DX03 Fenspiride
